Please assess the completion status of the following clinical trial:

Trial Title: Sildenafil (Viagra) Treatment of Subacute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with ischemic stroke between 4 and 7 days after symptom onset.~* Patients age 18-80 years old.~* NIHSS score of 5-21 prior to treatment (within each cohort, there will be no more than 4 patients with NIHSS \< 9 and no fewer than 4 patients with NIHSS \> 11).~* Signed IRB-approved informed consent by patient or authorized representative.~Exclusion Criteria:~General:~* Participation in another study with an investigational drug or device.~* Women known to be pregnant, lactating, or of childbearing potential with a positive urine beta-HCG.~* Patients who cannot receive oral medications.~* Patients using sildenafil or other phosphodiesterase inhibitors within the previous 7 days of stroke.~Safety Related:~* Unstable angina.~* Myocardial infarction within 3 months.~* Current use of nitrate agents.~* Current use of alpha-channel antagonists.~* Current use of medications that inhibit the cytochrome p450 3A4 system. These medications include: amiodarone, aprepitant, bosentan, cimetidine, cisapride, clarithromycin, delavirdine, diltiazem, efavirenz, erythromycin, fluconazole, fluvoxamine, grapefruit juice, imatinib, itraconazole, ketoconazole,loratadine, mibefradil, mifepristone (RU-486), niacin, nefazodone, quinidine, quinine, ritonavir, saquinavir, tacrolimus, verapamil, voriconazole.~* St. John's Wort and phenytoin (inducers of cytochrome P450 3A4)~* Baseline systolic blood pressure less than 100 mmHg.~* Penile deformities.~* Creatinine \> 1.5.~* Abnormal liver function studies.~* Patients with a previous history of sudden monocular vision loss Potentially Interfering with Outcomes Assessment:~* Prior history of dementia.~* Patients without fixed address or those deemed unlikely to present for follow-up by the investigator.~* Patients whose life expectancy is less than 90 days.~* Pre-stroke modified Rankin score \> 2.~* Glucose greater than or equal to 400 mg/dL at presentation.~* Other serious illness (e.g., severe hepatic, cardiac, or renal failure; acute myocardial infarction; or a complex disease that may confound treatment assessment).~* Previous stroke or TIA within 30 days.~* Allergy or hypersensitivity to sildenafil or other phosphodiesterase inhibitors.~* History of sudden monocular visual disturbance.~* History of sudden unilateral hearing problem.~Imaging Related:~* Evidence of primary intraparenchymal hemorrhage on initial neuroimaging study.~* Neuroimaging evidence of nonvascular cause for the neurological symptoms.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sildenafil (Type: EXPERIMENTAL): Orally administered sildenafil in addition to usual care.
- Usual post-stroke care (Type: ACTIVE_COMPARATOR): Usual post-stroke treatment including physical, occupational, and speech therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).